Oryzon Genomics - FDA green light for SCLC combination trial
With the FDA investigational new drug (IND) application clearance, Oryzon can commence its Phase I/II cooperative research and development...
301 Views
Oryzon Genomics - Third time is a charm; INNOVATIVE SME Seal
For the third consecutive time, Oryzon Genomics has received the INNOVATIVE SME Seal from the Spanish Ministry of Science and Innovation. This...
409 Views
Oryzon Genomics - Approaching a period of inflection
ORY FY23 results announcement covered an eventful period for the company’s pipeline, capped by the release of top-line data from the Phase IIb...
225 Views
Oryzon Genomics - KOL event: Offering a real-world solution in BPD
Oryzon hosted a key opinion leader (KOL) event highlighting the potential of vafidemstat in borderline personality disorder (BPD). The KOLs...
163 Views
Oryzon Genomics - PORTICO update with planned FDA EoP2
Oryzon Genomics has announced top-line results for the Phase IIb trial (PORTICO) assessing vafidemstat in borderline personality disorder (BPD),...
262 Views